BenevolentAI Company
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.
.png)
.png)
(Reupload).png)
.png)
Technology:
Artificial Intelligence, Big Data, Biotechnology, Machine Learning, Neuroscience
Industry:
End-to-end Drug Development
Headquarters:
London, England, United Kingdom
Founded Date:
2013-11-13
Employees Number:
51-100
Funding Status:
Private Equity
Investors Number:
6
Total Funding:
292000000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2019-09-17
Last Funding Type:
Private Equity
Register and Claim Ownership